Magforce AG is primarily active in the medical technology industry.

The main competitors of Magforce AG in the market include companies such as Varian Medical Systems, Elekta AB, and Accuray Incorporated. These companies also operate in the medical technology industry and offer innovative solutions for cancer treatment. However, Magforce AG distinguishes itself through its unique NanoTherm therapy, which utilizes magnetic nanoparticles to selectively heat and destroy cancer cells. With its cutting-edge technology and focus on personalized medicine, Magforce AG has gained a competitive edge in the market.

Magforce AG is a leading medical technology company specializing in nanomedicine. Founded in 1997, the company has a strong background of innovation and is headquartered in Berlin, Germany. Magforce has developed a revolutionary therapy called NanoTherm, which utilizes magnetic nanoparticles to treat solid tumors. The company's therapy has shown promising results in clinical trials and has received regulatory approvals in Europe. With its cutting-edge technology and commitment to improving cancer treatment, Magforce AG is poised to make a significant impact in the field of oncology.

Magforce AG has achieved several significant milestones. Firstly, the company successfully developed and received regulatory approval for its proprietary medical device, NanoTherm therapy, which utilizes magnetic nanoparticles to treat solid tumors. Additionally, Magforce AG established treatment centers in Germany and opened international centers in key markets such as Spain and Poland. The company has also obtained important certifications, including CE marking and ISO 13485 certification, further validating the safety and quality of its technology. Furthermore, Magforce AG has entered into strategic collaborations with renowned institutions and companies, enhancing its position in the field of nanotechnology and advancing the potential for groundbreaking cancer treatments.

Magforce AG is primarily present in Germany, where it is headquartered. It is a leading medical technology company focused on the development and commercialization of innovative medical devices, particularly in the field of nanomedicine. As a German-based company, Magforce AG operates mainly within the German market and has established a strong presence in the region. It leverages its expertise and technology to provide cutting-edge solutions for medical treatments, with a focus on improving patient outcomes and enhancing quality of life. Magforce AG is committed to revolutionizing cancer therapy and making a positive impact in the field of medical innovation.

Magforce AG represents a strong set of values and a clear corporate philosophy. The company focuses on innovative medical technology solutions, particularly in the field of nanotechnology. Magforce AG is dedicated to improving the lives of patients through pioneering therapies, such as its NanoTherm therapy system. With an emphasis on research, development, and commercialization, the company strives to provide effective, safe, and patient-centric healthcare solutions. Magforce AG's commitment to excellence, scientific rigor, and continuous improvement is evident in its pursuit of breakthrough therapies and advancements in the fight against cancer.

Analysts currently set an average price target of 10,28 EUR for the Magforce stock (median: 10,28 EUR), implying +342 450,0 % versus the latest price. The consensus is based on 5 analyst ratings.

Magforce Analyytikkojen kursstavoitteet 2026

5 analysts currently rate the Magforce stock: 4 recommend buying, 1 holding and 0 selling.

Magforce Analyytikkojen kursstavoitteet 2026

The Magforce share (MF6.SG) is listed on 11 stock exchanges, including: NASDAQ (MGFRF), XETRA (MF6.DE), Frankfurt (MF6.F), München (MF6.MU), Stuttgart (MF6.SG), Düsseldorf (MF6.DU), Berlin (MF6.BE), Hamburg (MF6.HM).

The Magforce AG is an innovative company specializing in the development and marketing of innovative therapies for the treatment of cancer. The company's business model revolves around the NanoTherm technology, which allows for the direct targeting and destruction of cancer cells while preserving healthy tissue. The NanoTherm technology is based on the generation of magnetic fields that are injected into nano-particles. These particles are then introduced specifically into cancer cells and heated by applying the magnetic field. This process causes the cancer cells to die while sparing the surrounding healthy tissue. In addition to the development of NanoTherm technology, Magforce AG also offers products for the diagnosis and monitoring of cancer conditions. Among these is the MagForce Nanoparticle Therapy System (NTS), which is used clinically for the treatment of brain tumors. The NTS is a medical device that generates magnetic fields to heat nanoparticles within the body. The effects can be monitored using MRI or CT scans. Another important aspect of Magforce AG's activities is collaboration with other companies and institutions in the development of new therapies and products. The company provides its expertise and technology and works closely with research and industry partners to create innovative and effective treatment options for cancer patients. The NanoTherm technology of Magforce AG is applied in various areas of cancer treatment, with a particular focus on brain tumors. The company has already achieved promising results in this field and has demonstrated the effectiveness and safety of the therapy through clinical studies. In addition to brain tumor treatment, Magforce AG is also working on developing therapy options for other types of cancer, such as prostate cancer and pancreatic carcinoma. The NanoTherm technology and NTS are also expected to be utilized in these areas. In conclusion, Magforce AG is an innovative company in the field of cancer therapy. Its business model is based on the development and marketing of therapies and products based on NanoTherm technology. In addition to brain tumor treatment, the technology is intended to be used in other types of cancer. The company collaborates closely with research and industry partners to develop innovative therapies and meet the needs of cancer patients.

Liikevaihtoa ei voida laskea Magforce:lle tällä hetkellä.

Voittoa ei voida laskea Magforce:lle tällä hetkellä.

P/E-suhdetta ei voida laskea Magforce:lle tällä hetkellä.

P/S-suhdetta ei voida laskea Magforce:lle tällä hetkellä.

Magforce:n Eulpool-laatuscore on 2/10.

Magforce:n ISIN on DE000A0HGQF5. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Magforce:n WKN on A0HGQF. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Magforce:n ticker on MF6.SG. Tämä pörssinoteeraus käytetään Magforce-osakkeiden kauppaan pörssissä.

Magforce maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

Magforce kuuluu sektoriin 'Terveydenhuolto'.

Magforce:n osingot jaetaan valuutassa EUR.